Skip to content

Autologous Chondrocyte Implantation in the Patellofemoral Joint

Autologous Chondrocyte Implantation in the Patellofemoral Joint

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00212849
Enrollment
35
Registered
2005-09-21
Start date
1995-01-31
Completion date
2005-08-31
Last updated
2005-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chondrosis, Patellar Articular Cartilage Lesions, Trochlear Articular Cartilage Lesions

Keywords

Articular Cartilage Lesions, Patellar lesions, Trochlear lesions, Patellofemoral joint, Carticel, Autologous Chondrocyte Implantation

Brief summary

The purpose of this study is to measure the outcomes of patients who have articular cartilage lesions in the patellofemoral joint and are treated with the Autologous Chondrocyte Implantation.

Detailed description

Cartilage restoration, in general, is a relatively new option for the treatment of articular cartilage lesions primarily of the knee. In the initial autologous cultured chondrocyte transplantation (ACT or, by others implantation, thus ACI) reported by Peterson et. al., the results of femoral lesions were favorable, while 5 of 7 patellofemoral treatments were poor. In the United States, the expedited FDA approval based on these results excluded the patella. As a result, in the United States, it has been difficult to further evaluate use of ACI at the patellofemoral joint in light of the exclusion of off label uses by many governmental and private insurance programs. Nevertheless, a growing body of knowledge is accumulating outside the United States that the use of ACI at the patella is a viable option and soon similar findings will be published in the US by Minas et. al. (accepted for publication)

Interventions

None listed

Sponsors

Genzyme, a Sanofi Company
CollaboratorINDUSTRY
Orthopaedic Research Foundation
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Carticel Implantation of the patella and/or trochlear lesion. Patients who have reached their two-year follow-up date. All patients included in sequential order.

Exclusion criteria

* Patients that have had a microfracture in the knee joint at the same time as Carticel Implantation. Patients that have implantable lesions other than the patella and trochlea.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026